EMfemme 360 in London: what it is, what the evidence shows, and who it suits

Much of what is written about EMfemme 360 promises "feminine rejuvenation", "tightening", "123% improvement", no pain and "no side effects". This guide is written by the team that offers EMfemme 360 at our clinic on Devonshire Place and reviewed by our clinician. It gives you what the device is and what it is cleared for, what the one study and the independent trials of similar devices measured, what NICE says you should be offered first, what a session involves, who should not have it, and how it differs from the Emsella chair.

What EMfemme 360 is

Radiofrequency is an electrical current that heats tissue. In EMfemme 360 the current runs at 3.2 MHz from a slim applicator, the BTL-785-3, which the clinician inserts into the vaginal canal and moves slowly in and out so the whole circumference is warmed to between 40 and 45 degrees. A thermometer shows the tissue temperature on the screen, the device measures the tissue's resistance a thousand times a second and adjusts the power, and the clinician raises the setting from about 65% only as far as you find comfortable. The tip is single-use. The heating phase lasts about eight minutes; the appointment, with the consultation and the examination, about 30 in our practice. The manufacturer's clinical guide also describes an external protocol over the labia, the vaginal opening and the perineum, three to five minutes a zone; the published study treated the canal only.

The manufacturer's international page describes it as "the shortest non-invasive radiofrequency treatment for vaginal health, used both intravaginally and externally", meant to "improve vaginal laxity, labial laxity, and sexual dysfunction", and cites "83% of women reported pain-free sex after treatment" and "93% patient satisfaction", both marked "data on file"; the 83% matches the one published study described below. The idea is that controlled heat in the mucosa and the tissue beneath increases blood flow and triggers remodelling of collagen and elastin over the following weeks. For other radiofrequency devices there are small biopsy studies showing new collagen; for EMfemme 360 there are none, and "proven to increase elastin and collagen" is the exact claim the US regulator asked the manufacturer to substantiate for the predecessor product in 2018.

The manufacturer's own film on our homepage and the "360 degree" in the name describe the circular energy pattern; they are the manufacturer's description, not an outcome.

What it is cleared for, and what it is not

• In the United States, the BTL-785 platform with the BTL-785-3 applicator is 510(k) cleared, most recently in March 2026, "to provide heating for the purpose of elevating tissue temperature for selected medical conditions such as temporary relief of pain, muscle spasms, and increase in local circulation". The words vaginal, vulvar, pelvic, laxity, incontinence and sexual function appear nowhere in the five clearances we reviewed. "FDA approved" is wrong twice over: a clearance is not an approval, and the clearance is for heating.
• The 2018 safety communication. On 30 July 2018 the US Food and Drug Administration warned against energy-based devices for vaginal "rejuvenation" or cosmetic procedures: "To date, we have not cleared or approved for marketing any energy-based devices to treat these symptoms or conditions, or any symptoms related to menopause, urinary incontinence, or sexual function", naming vaginal burns, scarring, pain during intercourse and chronic pain as possible harms. It wrote to several manufacturers, including BTL about the predecessor Ultra Femme 360, and recorded that they responded with adequate corrections. We have found no later FDA statement that changes this.
• In Europe and the UK, the manufacturer's UK site states the intended purpose of the EMfemme applicator as "the treatment of sexual dysfunction after vaginal delivery by means of improvement of vaginal laxity". That is the one stated purpose; it does not cover menopause, dryness or incontinence.
• What UK guidelines say. NICE has no guidance on vaginal radiofrequency that we could find. It says vaginal laser should not be offered for menopausal genitourinary symptoms outside a randomised trial (2024), and its incontinence guideline puts supervised pelvic floor muscle training of at least three months first for stress and mixed incontinence. The European obstetrics board (2024, on vaginal laser) called for high-quality evidence before routine use, and the American urogynaecology society (2020, laser and radiofrequency) said long-term safety and efficacy need to be evaluated. The UK advertising regulator upheld complaints in February 2019 against a clinic advertising "vaginal tightening" without documentary evidence for the claims.

Does EMfemme 360 work? What the evidence shows

For EMfemme 360 itself: one small, uncontrolled study. For radiofrequency devices of the same broad kind, made by other manufacturers and mostly multipolar radiofrequency with a pulsed magnetic field where EMfemme is monopolar, so the results may not carry over: a handful of small sham-controlled trials with short-term, self-reported improvements in laxity and a weak or absent effect on sexual function scores and on incontinence.

• The EMfemme 360 study (2022). 35 postmenopausal women with severe pain on intercourse and vaginal atrophy had three eight-minute sessions a month apart and were assessed two months after the last. Of those who had been unable to have intercourse, 83% could do so without pain; a vaginal health score rose from 7.7 to 18.7 on a 5 to 25 scale; pain at examination fell from 6.6 to 1.4 on the scale used; 93% were satisfied. There was no comparison group, no blinding, the authors call the group "rather limited" and the follow-up too short to show how long the effect lasts; they declare no conflict of interest and give no funding statement, and the device is BTL's. It is a study of painful intercourse in menopause, not of laxity after childbirth and not of incontinence.
• The manufacturer's registered study. BTL registered a 25-woman study combining the EMfemme applicator with its Emsella chair, completed in April 2024, with no results posted; because it combined two devices it cannot show what EMfemme did on its own.
• Similar radiofrequency devices, laxity. A 2026 systematic review found three sham-controlled radiofrequency trials in which women were about three times as likely to report a laxity improvement with active treatment as with sham, and two trials in which the sexual function score rose by 1.6 points on a 2 to 36 scale, where a change of about 4 is usually taken as meaningful. It rated the evidence low-certainty, short-term and subjective, and said pelvic floor training should come first. A 2024 trial of 76 women with vaginal atrophy found a vaginal health score better than sham at every visit except the last, at twelve months, a laxity score better than sham at four, six and twelve months, and sexual function no better than sham at any visit. A 2024 trial against pelvic floor training found training did better at six months.
• Similar devices, menopause symptoms. Four small trials of radiofrequency against vaginal oestrogen (156 women) gave a borderline advantage to radiofrequency on the total sexual function score and no difference on any part of it (2026).
• Incontinence. A 2026 meta-analysis of ten sham-controlled trials of energy devices for stress incontinence found a small average change on a symptom score whose prediction interval included no benefit, and called the radiofrequency evidence "insufficient". The one sham-controlled radiofrequency trial we found measured leakage by pad weight, which did not differ from sham; its one-year "success" rate was higher with radiofrequency (70% against 39%) but no other outcome differed. In the EMfemme study, 16 women said their incontinence improved, with no questionnaire or pad test. We do not offer EMfemme 360 for incontinence.
• The wider lesson from vaginal laser. Across 114 papers on vaginal laser, half the randomised trials found no difference from control, and the effect shrank as study quality rose (2022). Radiofrequency has not yet been tested at that scale.

So the honest picture: some women report a real improvement in comfort, lubrication and a sense of laxity for a few months after a course, the trials that used a sham arm show part of that is the device and part is not, nobody knows how long it lasts, and some advertised figures are ones we could not trace to a study.

Who EMfemme 360 suits, and who it does not

It suits a woman with a sense of vaginal laxity after a vaginal delivery, the manufacturer's stated UK purpose, who has already had supervised pelvic floor training or cannot do it; a woman who wants the external protocol for labial laxity, knowing there is no published outcome data for it; or a woman with discomfort during intercourse or dryness around the menopause, the group the one published study treated, who has covered vaginal oestrogen and moisturisers with her GP first. In every case: examined, no untreated condition, and accepting that the evidence is early, the effect modest and its duration unknown. The manufacturer's UK stated purpose covers only the laxity use; its international description and its cited studies cover the rest, and we tell you which is which.

It does not suit, and we will say so:

• Anyone seeking treatment for urinary leakage. Incontinence needs its type established and a supervised pelvic floor programme first, and the device in our group with a US-cleared incontinence indication is the Emsella chair, not this one.
• Anyone who has not been examined. Prolapse, infection, atrophy that needs oestrogen, and anything that needs a gynaecologist come first.
• Anyone looking for a "tightening" result, a cosmetic change to the labia, or a fix that lasts for good. The published evidence is internal only, there is no external or labial outcome data, and we found no study that followed women beyond twelve months.
• Pain on intercourse that has not been assessed. Pain has causes that need a diagnosis before any heat treatment.

Who should not have it, from the manufacturer's clinical guide, which we hold (its list runs to 33 items; these are the main ones), checked by the doctor at your consultation:

• Pregnancy, breastfeeding or IVF treatment; the postpartum period; menstruation on the day.
• An infection or inflammation in the area, including a sexually transmitted infection, active sores, psoriasis, eczema, a rash or rosacea; impaired immunity; tuberculosis or hepatitis; a fever.
• Any metal or fixed implant near the area or the return electrode, which covers pelvic mesh and may cover a copper coil; a pacemaker, defibrillator or any active implant.
• Skin cancer or any current cancer, a history of malignant cancer, pre-malignant moles; radiotherapy or chemotherapy.
• A clotting disorder or anticoagulants; cardiovascular disease; collagen disease; a skin autoimmune disease; isotretinoin in the last 12 months.
• Surgery, dermabrasion or a peel in the area in the last three months; unhealed wounds.
• Reduced sensation in the area, acute nerve pain or neuropathy, kidney or liver failure, poorly controlled diabetes or another endocrine disorder, varicose veins or swelling in the area.
• A prolapse beyond the vaginal opening with a thin wall to the back passage.
• Being in a pelvic floor physiotherapy programme at the time: the manufacturer lists it as a contraindication, so we treat you after the programme, not during it.
• Cervical screening is not mentioned by the manufacturer; as our own precaution we ask that yours is up to date.

What a session is like, step by step

1. Consultation and examination. A doctor takes your history, including childbirth, menopause, continence and any pain, examines you, and tells you what the first-line options are and whether you have had them. If what you need is pelvic floor physiotherapy, vaginal oestrogen or a gynaecologist, we say so and do not treat. Consultations and follow-up reviews are free, and a female practitioner can deliver the treatment if you ask.
2. Preparation. You undress from the waist down and lie as for a smear test. A new single-use tip goes on the applicator, with a water-based gel, in our practice.
3. The treatment. In our practice the applicator is inserted a few centimetres and moved slowly in and out, with a return electrode on your back or thigh as the manufacturer's guide specifies. You feel warmth building, "comfortable heat" in the manufacturer's words; the clinician raises the power only as far as you say is comfortable and the screen shows the tissue temperature. The heating phase lasts about eight minutes, the manufacturer's standard setting within a range of two to ten.
4. Straight after. You dress and go. Some women notice a little discharge, spotting or irritation for a day or two, particularly after the first session; in the one published study most women had some of these.
5. The course. Three sessions, two to fourteen days apart in the manufacturer's clinical guide. The published study spaced them a month apart; our practice is weekly, inside the manufacturer's range, which no study has tested on its own, and we tell you that. We review you six months after the course.

How many sessions, when you see the result, how long it lasts

Results you can check

There are no before-and-after photographs for this treatment, and we do not publish patients' descriptions as evidence. Our reviews are collected through review.clinic, and the badge on this page links to them: 4.9 out of 5 from 49 reviews in October 2026, with 100% of reviewers saying the treatment was worth it. Read them as experiences, not as trial results. At your six-month review you compare how you feel against the notes we took before you started.

EMfemme 360 compared with the alternatives

EMfemme 360 vs Emsella. Different devices for different problems, both made by BTL. Emsella makes the pelvic floor muscles contract and is the one with a cleared incontinence indication; EMfemme heats the vaginal tissue and has none. Leakage needs a continence assessment and pelvic floor training first; Emsella is the device in our group with a US incontinence clearance, and NICE does not cover it.

EMfemme 360 vs pelvic floor training. Training is first line and beat radiofrequency at six months in the one trial that compared them. EMfemme is for after it, not instead of it.

EMfemme 360 vs vaginal oestrogen. For menopausal dryness and painful sex, NICE puts vaginal oestrogen first, says serious adverse effects are very rare, and lists moisturisers and other options for women who cannot or prefer not to use it. "A hormone-free alternative to HRT" is a sales line unless it comes with that sentence.

EMfemme 360 vs vaginal laser. NICE says laser should not be offered for menopausal symptoms outside a trial, and the sham trials of laser split evenly. Radiofrequency has no NICE statement and smaller trials. Neither is a first-line treatment.

EMfemme 360 vs surgery. For stress incontinence after failed non-surgical treatment NICE lists colposuspension and an autologous sling. For appearance, the American college of obstetricians said in 2007 that "vaginal rejuvenation" surgery was not medically indicated. No trial compares radiofrequency with surgery.

Side effects, and the risks nobody writes about

Expected, from the EMfemme study: a watery discharge in 70% of women, bleeding in 50%, itching at the opening in 45%, a burning feeling in 30% and painful urination in 20%, mostly after the first session, mild, and gone within one to two days. The authors reported no complications. "No side effects" is not what the study says.

Reported by the US regulator and in adverse-event reports, with how often unknown: burns, scarring, pain during intercourse and persistent pain. In 39 US reports on vaginal energy devices, most were injuries, and radiofrequency devices were more often linked to loss of sensation than lasers were. Reports are not rates, and under-reporting is acknowledged, but the harms are real and the reason the temperature is watched and your feedback matters: reduced sensation in the area is a reason not to treat.

The risks nobody writes about are two. First, the untreated condition: a prolapse, an atrophy that needs oestrogen, a pain with a cause, a leakage that needs a continence assessment, each of which a "wellness" session can delay. Our examination exists to catch that, and if you need your GP, a physiotherapist or a gynaecologist we say so and do not treat. Second, the claims: a course bought on a "123% improvement" is a course bought on a figure we could not trace to any study.

How to choose an EMfemme 360 clinic in London

• Ask who examines you and what they are. Ours is a doctor, and this guide is reviewed by Dr Marie Duggan, GMC 7488383. A female practitioner can deliver the treatment if you prefer.
• Ask whether you have had the first-line treatment for your symptom, and whether the clinic will refer you for it. If nobody mentions pelvic floor training or vaginal oestrogen, ask why.
• Ask what the device is cleared for. Tissue heating in the US; laxity after vaginal delivery per the manufacturer in Europe. Anything about incontinence, "rejuvenation" or "tightening" is marketing.
• Ask for the evidence behind any percentage. The only EMfemme 360 study has 35 women and two months.
• Ask about the tip. Single-use; ours is opened in front of you.
• Ask what happens if it hurts, bleeds or burns, and who you call.
• Treat any promise of no pain, "no side effects", "no downtime", "lasts twelve months" and any claim of FDA approval as warning lights.

Aftercare

Our advice, pending the manufacturer's aftercare sheet: a little discharge, spotting or irritation for a day or two is expected and a panty liner is enough; avoid intercourse, tampons, baths, swimming and saunas for 24 to 48 hours; and do not book a session during your period. Tell us about bleeding that is more than spotting, pain, a burning that lasts beyond two days, a fever, a change in sensation, or any pain during intercourse that is new, and see your GP or call 111 for anything that worries you.

Frequently asked questions